Innovation set to help patients at risk of falls and fractures
United Kingdom – Royal Philips (NYSE: PHG; AEX: PHIA) today launched HomeSafe in the UK, a robust, analytics-driven telecare solution designed to reduce risk, lower costs and improve outcomes for patients who are at risk of falling. Unveiled at EHI Live in Birmingham, HomeSafe, featuring Auto-Alert is a telecare system, which uses patient-centred devices and the latest in data analytics to help care givers manage their populations at risk of falls, helping them optimise resources and improve care. Auto-Alert is the latest addition to the Philips population health management portfolio, as part of the Philips vision of ‘Connecting care for continuous health’– a way to better analyse, manage and take shared responsibility for the health of individuals and populations. Continuous Health means creating immediate and uninterrupted connections and interactions that promote ongoing health and proactive care, from hospital to home. Falling is the leading cause of injury related death in people over 75 in the UK1. Auto-Alert therefore represents an important step in population health management through its highly accurate fall detection, ensuring help is provided when needed. The Philips innovative approach to falls management is set to include falls prevention from 2017, when the CareSage predictive analytics engine comes onto market in the UK. CareSage, already available in the US, will be hosted on the Philips HealthSuite digital platform. “Falls in older people cost the NHS £2.3 billion per year2, with falls and fractures in the over-65’s accounting for four million hospital bed days each year in England alone3. Yet 27% of hospitalisations may be avoided with proactive care4” said Andy Calchadora Business Development Director UK&I at Philips Home Monitoring. “With their ‘intelligence to reduce hospitalisation’ mission, the HomeSafe innovations we are launching in the UK market are set to reduce pressure on health and social care budgets through the reduction in avoidable hospital admissions as well as improved patient outcomes and well-being.” The HomeSafe Auto-Alert is now available in the UK across a range of pendant devices. Highly accurate, Auto-Alert detects 95% of true falls with its advanced fall detection algorithm. It combines calculations of altitude drop, velocity, orientation change and impact to recognise when a fall has occurred. The pendant is waterproof, allowing the patient to wear the device in the bath or shower where falls are common. Auto-Alert is designed to automatically contact the care team when a fall is detected. “At EHI Live, Philips is showcasing its growing portfolio of telecare, with Auto-Alert an important innovation for older patients in this field” said Andy Calchadora. “The Philips HomeSafe systems are transforming falls management by a focus on proactive care. Auto-Alert has the potential to improve the outcomes of older patients at risk of falls and fractures, as its automatic fall detection means patients receive care when it’s needed. This is the first step in the UK market Philips telecare offering – next year Philips is set to launch a multi-sensor device with a built in algorithm for falls prevention, going one step further”. 1 http://www.nhs.uk/conditions/Falls/Pages/Introduction.aspx 2 https://www.nice.org.uk/guidance/cg161/chapter/introduction 4 https://www.lifeline.philips.com/content/dam/PLL/PDF/PopHealthManagementWP.pdf
Sally Hilson Philips Group Communications Mob: +44 (0)7825 454 403 E-mail: sally.hilson@philips.com For access to further media materials, visit http://releasd.com/55e8/telecare2016
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 70,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORi™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7® wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. All published clinical studies on Masimo products can be found at www.masimo.com/cpub/clinical-evidence.htm.
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
You are about to visit a Philips global content page
ContinueSelect country/region
United Kingdom (English)